SRTA — Strata Critical Medical, Inc. stock price, charts and financials
QT62Strata Critical Medical, Inc.Strata Critical Medical, Inc. (NASDAQ: SRTA) is a Healthcare company in the Medical - Care Facilities industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
Latest market price
5.34
-0.04-0.74%
News
Down 0.7% — Strata Critical Medical: Pivot To M&A Offers Near-Term Upside, But TAM Constraints Remain (SeekingAlpha).
Medium confidence
TA
Loading chart...
Snapshot
| Index | - | P/E | 10.68 | EPS (ttm) | 0.50 | Insider Own | 28.49% | Shs Outstand | 86.53M | Perf Week | 2.69% |
| Market Cap | 462.05M | Forward P/E | - | EPS next Y | 0.00 | Insider Trans | -0.58% | Shs Float | 45.00M | Perf Month | -9.34% |
| Enterprise Value | 442.05M | PEG | - | EPS next Q | 0.01 | Inst Own | - | Short Float | 10.06% | Perf Quarter | -9.18% |
| Income | 39.00M | P/S | 1.80 | EPS this Y | -118.50% | Inst Trans | - | Short Ratio | 3.98 | Perf Half Y | 22.76% |
| Sales | 256.00M | P/B | 1.66 | EPS next Y | 103.60% | ROA | 12.09% | Short Interest | 4.53M | Perf YTD | 11.02% |
| Book/sh | 3.22 | P/C | 20.09 | EPS next 5Y | - | ROE | 14.27% | 52W High | 6.50 -17.85% | Perf Year | 2.69% |
| Cash/sh | 0.27 | P/FCF | - | EPS past 3/5Y | - | ROIC | -7.09% | 52W Low | 3.95 35.19% | Perf 3Y | 73.94% |
| Dividend Est. | - | EV/EBITDA | - | Sales past 3/5Y | 10.50% 53.66% | Gross Margin | 20.56% | Volatility | 4.20% 3.94% | Perf 5Y | -45.79% |
| Dividend TTM | - | EV/Sales | 1.73 | EPS Y/Y TTM | 242.86% | Oper. Margin | -7.97% | ATR (14) | 0.23 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 2.64 | Sales Y/Y TTM | 2.81% | Profit Margin | 15.71% | RSI (14) | 45.08 | Recom | 2.00 |
| Dividend Gr. 3/5Y | - | Current Ratio | 2.64 | EPS Q/Q | -140.00% | SMA20 | -3.97% | Beta | 2.42 | Target Price | 7.25 |
| Payout | 0.00% | Debt/Eq | 0.01 | Sales Q/Q | 2.82% | SMA50 | -2.81% | Rel Volume | 0.87 | Prev Close | 5.38 |
| Employees | 327 | LT Debt/Eq | 0.01 | Earnings | Nov 09 | SMA200 | 3.89% | Avg Volume | 1.03M | Price | 5.34 |
| IPO Date | Nov 05, 2019 | Option/Short | Yes / Yes | EPS/Sales Surpr. | -500.00% 7.24% | Net Debt/EBITDA | 1.29 | Volume | 896,494 | Change | -0.74% |
Analyst Ratings
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Sep-17-25 | Reiterated | Lake Street | Buy | $7.25 |
Latest News· Times ET
Sep-16-26
Sep-16-2602:15AM
Sep-10-26
Sep-08-26
Sep-08-2601:05PM
Aug-24-26
Aug-24-2609:01AM
06:56AM
Aug-06-26
Aug-06-2609:21AM
Aug-05-26
Aug-05-2607:40AM
Aug-04-26
Aug-04-2606:56AM
06:49AM
03:00AM
Strata Critical Medical Announces Second Quarter 2026 Resultsglobenewswire.com
Jul-21-26
Jul-21-2612:05PM
Jul-07-26
Jul-07-2604:15AM
Jun-24-26
Jun-24-2605:01AM
Company
Strata Critical Medical, Inc. is dedicated to supporting healthcare providers throughout the United States by offering swift logistical management and specialized medical assistance. A significant part of their operations involves the movement of human organs for transplant, utilizing both aerial and ground transportation methods. Founded in 2014, the organization previously operated under the name Blade Air Mobility, Inc. and is set to officially change its name to Strata Critical Medical, Inc. in August of 2025. Its primary corporate office is located in New York, New York.
Ownership
Per-holder 13F data hasn't been ingested for this ticker yet.
Financial Statements
DataTimeframe
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 9/30/2021 | FY 2020 9/30/2020 | FY 2019 9/30/2019 | |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 256 | 197 | 249 | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 203 | 156 | 190 | — | — | — | — | — | |
| Gross Profit | 53 | 41 | 59 | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 59 | 61 | 90 | — | — | — | — | — | |
| Research and Development | 0 | 3 | 3 | — | — | — | — | — | |
| Other Operating Expense | 14 | -1 | 0 | — | — | — | — | — | |
| Operating Income | -20 | -22 | -34 | — | — | — | — | — | |
| Interest Expense | 0 | 0 | 0 | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | -3 | 2 | 6 | — | — | — | — | — | |
| Net Income Before Taxes | -24 | -20 | -28 | — | — | — | — | — | |
| Income Taxes | 0 | 0 | 0 | — | — | — | — | — | |
| Consolidated Net Income | 39 | 41 | -27 | — | — | — | — | — | |
| Net Income From Continuing Operations | -24 | -20 | -27 | — | — | — | — | — | |
| Net Income | 39 | 41 | -27 | — | — | — | — | — | |
| EPS (Recurring) | 0.50 | 0.50 | -0.35 | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | 0.50 | 0.50 | -0.35 | — | — | — | — | — | |
| EPS (Diluted) | 0.50 | 0.50 | -0.35 | — | — | — | — | — | |
| EBITDA | -10 | -6 | -22 | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 10.68 | 9.62 | — | — | — | — | — | — | |
| Price To Sales Ratio | 1.79 | 2.00 | 1.31 | — | — | — | — | — | |
| Gross Margin | 20.70 | 20.81 | 23.69 | — | — | — | — | — | |
| Operating Margin | -7.81 | -11.17 | -13.65 | — | — | — | — | — | |
| Net Margin | 15.23 | 20.81 | -10.84 | — | — | — | — | — | |
| Shares Outstanding | 86 | 82 | 77 | — | — | — | — | — | |
| Market Capitalization | 459 | 394 | 327 | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — |
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
Insider Trading
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Love Reginald | Director | Aug 10 '26 | Sale | 5.75 | 5,091 | 29,273 | 146,481 | Aug 13 |
| Cohen Amir | Chief Accounting Officer | Jun 08 '26 | Sale | 5.87 | 4,655 | 27,325 | 146,608 | Jun 10 |
| Heyburn William A. | Co-CEO and CFO | Jun 08 '26 | Sale | 5.87 | 31,671 | 185,909 | 1,548,997 | Jun 10 |
| Tomkiel Melissa M. | Co-CEO and General Counsel | Jun 08 '26 | Sale | 5.87 | 29,730 | 174,515 | 1,892,774 | Jun 10 |
| Wunsch Scott M | CEO, Logistics | Jun 08 '26 | Sale | 5.87 | 5,550 | 32,579 | 625,574 | Jun 10 |
| Cohen Amir | Chief Accounting Officer | May 22 '26 | Sale | 5.91 | 40,575 | 239,798 | 151,263 | May 26 |
| Cohen Amir | Chief Accounting Officer | May 21 '26 | Sale | 5.79 | 10,300 | 59,637 | 191,838 | May 26 |
| Cohen Amir | Chief Accounting Officer | May 11 '26 | Sale | 5.79 | 14,306 | 82,832 | 202,138 | May 13 |
| Tomkiel Melissa M. | Co-CEO and General Counsel | Jan 02 '26 | Option Exercise | 0.18 | 276,960 | 49,853 | 1,643,362 | Jan 05 |
| Heyburn William A. | Co-CEO and CFO | Dec 09 '25 | Buy | 4.47 | 17,000 | 76,044 | 1,403,436 | Dec 10 |
| LAUCK ANDREW | Director | Dec 05 '25 | Buy | 4.37 | 5,000 | 21,825 | 135,642 | Dec 05 |
| Love Reginald | Director | Nov 20 '25 | Sale | 4.37 | 11,000 | 48,070 | 113,897 | Nov 24 |
| Love Reginald | Director | Nov 19 '25 | Sale | 4.31 | 11,000 | 47,434 | 124,897 | Nov 20 |
| Tomkiel Melissa M. | Co-CEO and General Counsel | Nov 07 '25 | Option Exercise | 0.18 | 27,778 | 5,000 | 1,400,420 | Nov 12 |
| Tomkiel Melissa M. | Co-CEO and General Counsel | Oct 22 '25 | Option Exercise | 0.18 | 55,556 | 10,000 | 1,270,372 | Oct 23 |
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.